© ACCESSWIRE
14.01.2026
ASBP
LISTED
NASDAQ
Aspire Biopharma Announces Reverse Stock Split
News Preview
ESTERO, FL / ACCESS Newswire / January 14, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced a reverse stock split of its issued and outstanding common stock, par value $0.01 per share, at...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.01.2026
FWBI
LISTED
NASDAQ
GridAI and the New Operating Reality of the Electric Grid
News Preview
BOCA RATON, FL / ACCESS Newswire / January 14, 2026 / For decades, managing the electric grid was largely a planning exercise. Operators forecast demand, built capacity, and adjusted slowly as conditions evolved. That model worked in an era when consumption patterns were predictable and infrastructure expansion could keep pace with growth.That oper...
Themefolio
Profiler
Peergroup
© Newsfile
14.01.2026
VIVI
LISTED
CSE
TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage
News Preview
Validation is expected to accelerate TempraMed's path to payor reimbursement for product portfolioHighlightsROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibilityConfirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investmentSup...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
14.01.2026
BNN
LISTED
XETR
BRAIN Biotech AG benefits from successful monetization of projects and strong corporate cost control
News Preview
FY 2024/25: BRAIN Biotech AG benefits from successful monetization of projects and strong corporate cost control
Challenging sales environment, but strong corporate cost control
Successful monetization of projects from the BRAINBioIncubator pipeline
Group’s cash position remains solid at € 6.2 million
ZWINGENBERG, Germany, January 14, 2026 – BRA......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
14.01.2026
BNN
LISTED
XETR
BRAIN Biotech AG profitiert durch erfolgreiche Monetarisierung von Projekten und starker Kostenkontrolle
News Preview
Geschäftsjahr 2024/25: BRAIN Biotech AG profitiert durch erfolgreiche Monetarisierung von Projekten und starker Kostenkontrolle
Herausforderndes Absatzumfeld, starke Kostenkontrolle im Unternehmen
Erfolgreiche Monetarisierung von Projekten aus der BRAINBioIncubator-Pipeline
Liquiditätsbestand des Konzerns mit 6,2 Mio. EUR weiterhin solide
ZWINGE......
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2026
GALD
LISTED
XWSX
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
News Preview
Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January 14-17, 2026. The company will share data from five abstracts on two neuromodulators from its portfolio, Relfydess – the first and only ready-to-use liquid neuromodulator de...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.01.2026
ZOMDF
LISTED
OTC
Zomedica Announces "Fourth Friday at Four" Webinar on January 23rd Focused on Digital Innovation & Technology-Driven Growth
News Preview
January session to highlight Zomedica's expanding digital capabilities and long-term innovation strategy ANN ARBOR, MI / ACCESS Newswire / January 14, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
ORNBV
LISTED
HEL
Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 14 JANUARY 2026 at 8:30 EET ...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.01.2026
SRT3
LISTED
XETR
Sartorius Expands Bio-Circular Product Offering for More Sustainable Bioprocesses
News Preview
Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon CertificationCertified raw materials significantly reduce dependence on fossil-based plasticsBio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturersCertified production network spans...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
IPN
LISTED
EURONEXT
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
News Preview
PARIS, FRANCE, 14 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of 14 across multiple neurological conditions at the TOXINS 2026 conference (14-17 January) in Madrid, Spain. Data presented highlighted the depth and diversity of evidence across multiple movement disorders — including post‑stroke spasticity, cervic...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
9926
LISTED
HKSE
Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
News Preview
HONG KONG, Jan. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemotherapy against a PD-1 inhibitor plus chemotherapy for the first-line (1L) treatment for advanced gastric (G)...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
13
LISTED
HKSE
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
News Preview
— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment —...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
14.01.2026
BCT
LISTED
TSX
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
News Preview
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 5,366,726...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
ALGN
LISTED
NASDAQ
Align Technology Sponsors 30 Invisalign® Treatments Through Smiles4Canada Program to Provide Orthodontic Care to Children and Teens
News Preview
Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced a new initiative with the Canadian Foundation for the Advancement...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2026
CNC
LISTED
NYSE
CENTENE CORPORATION TO HOST 2025 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS EARNINGS CALL
News Preview
ST. LOUIS, Jan. 13, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that it will release its 2025 fourth quarter and year-end financial results at approximately 6:00 a.m. ET on Friday, February 6, 2026, and host a conference call at 9:00 a.m. ET...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
GKOS
LISTED
NYSE
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
News Preview
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidanc...
Themefolio
Profiler
Peergroup
© Newsfile
13.01.2026
SHPH
LISTED
NASDAQ
Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever
News Preview
Gaithersburg, Maryland--(Newsfile Corp. - January 13, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), applauds the state of Utah which has become the first state in the United States to allow artificial intelligence systems to authorize prescription refills without direct physician involvement R...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
XRAY
LISTED
NASDAQ
Dentsply Sirona and Benco Dental Announce Expanded Partnership to Include Dental Technology Solutions
News Preview
Benco Dental will offer Dentsply Sirona’s full portfolio of dental technology solutions, in addition to the consumables portfolio. Expanding the decades-long relationship reflects a shared vision to advance connected dentistry by facilitating access to an integrated ecosystem that connects devices, software, and people—from scanning to designing an...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
PRAX
LISTED
NASDAQ
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
News Preview
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly c...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
TGTX
LISTED
NASDAQ
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
News Preview
Preliminary total global full year 2025 revenue of approximately $616 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
SLDB
LISTED
XNMS
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
News Preview
- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen -...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
RPID
LISTED
NASDAQ
Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
News Preview
LEXINGTON, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced preliminary unaudited fourth quarte...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
BBOT
LISTED
NASDAQ
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on January 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employmen...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
FHTX
LISTED
NASDAQ
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
News Preview
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its $50 million registered direct financing at a 30% premium. The registered di...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
BAYN
LISTED
XETR
Bayer Accelerates Pharma Growth on High-Value Portfolio
News Preview
On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026.
Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercia...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
TVTX
LISTED
NASDAQ
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
News Preview
Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026....
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
AGL
LISTED
NYSE
Law Offices of Frank R. Cruz Encourages agilon health, inc. (AGL) Shareholders To Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL) securities between February 26, 2025 and August 4, 2025, inclusive (the “Class Period”). agilon investors have until March 2, 2026 to file a lead plaintiff motion....
Themefolio
Profiler
Peergroup
© ActuNews
13.01.2026
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 13 januari 2026 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparantiekennisgeving...
Themefolio
Profiler
Peergroup
© ActuNews
13.01.2026
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – January 13, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on January 9, 2026, from Atlas Special Oppor...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
AGL
LISTED
NYSE
Law Offices of Howard G. Smith Encourages agilon health, inc. (AGL) Shareholders To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL) securities between February 26, 2025 and August 4, 2025, inclusive (the “Class Period”). agilon investors have until March 2, 2026 to file a lead plaintiff motion.
IF...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
IPN
LISTED
EURONEXT
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
News Preview
PARIS, FRANCE, 13 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven-Aza) in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults. IP...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
GNFT
LISTED
EURONEXT
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
News Preview
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 13 janvier 2026 – GENFIT (Euronext: GNFT), société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui le bilan semestriel du contrat de liqui...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
EL
LISTED
EURONEXT
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2025
News Preview
Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2025...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.01.2026
AYTU
LISTED
NASDAQ
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
News Preview
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, announced today that Josh Disbrow, Chief Executive Officer of...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2026
ILMN
LISTED
NASDAQ
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery
News Preview
The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2026
ILMN
LISTED
NASDAQ
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025
News Preview
SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025 ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Tim...
Themefolio
Profiler
Peergroup
© Newsfile
13.01.2026
TTI
LISTED
TSX
Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026
News Preview
San Diego, California--(Newsfile Corp. - January 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that an abstract outlining preliminary result...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
HOLX
LISTED
NASDAQ
Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening
News Preview
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced the launch of Ultimate Defense, a new educational campaign in the U.S. with women’s professional basketball player Erica Wheeler. The initiative aims to increase awareness about the importance of routine cervical cancer screening and encourage women to talk with their...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
“2026 ma...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
BAX
LISTED
NYSE
Baxter Introduces the Dynamo Series, a New Smart Stretcher to Help Address Common Challenges in Hospital Settings
News Preview
Baxter International Inc. (NYSE:BAX), an innovator in smart beds for med-surg and the intensive care unit, announced at the 2026 J.P. Morgan Healthcare Conference the upcoming U.S. launch of the Dynamo Series stretcher. The Dynamo Series is a stretcher designed to help alleviate the physical and cognitive burden on care teams1 and make it easier f...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
BAYN
LISTED
XETR
Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause
News Preview
Bayer today announced it has partnered with actress and menopause advocate Gabrielle Union-Wade on the ‘Life Doesn’t Stop for a Hot Flash’ campaign, which speaks to women with moderate to severe hot flashes due to menopause. The campaign encourages women to have an open and honest conversation with their healthcare provider about their hot flash e...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS13 January 2026 at 16.30 EET ...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
HUM
LISTED
NYSE
Humana Expands Cancer Care for Medicare Advantage Members Through Atlas Oncology Partnership
News Preview
Leading health and well-being company Humana Inc. (NYSE: HUM) today announced it is entering into a partnership with Atlas Oncology Partners to make cancer care simpler, more supportive and focused on improving patients’ quality of life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
IBRX
LISTED
NASDAQ
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
News Preview
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) clinical program in non-small cell lung cancer (NSCLC) based on two studies, QUILT-2.023 and QUILT-3.055. Across 151 patients spanning first-, second-, and later-line disease, ANKTIVA demonstrat...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
IDXX
LISTED
NASDAQ
IDEXX Announces CEO Succession
News Preview
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the promotion of Michael (Mike) Erickson, PhD, to President and Chief Executive Officer, effective May 12, 2026, at which time Jonathan (Jay) Mazelsky, President and CEO, will transition to the role of Executive Chair of IDEXX’s Board of Director...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
XTLB
LISTED
NASDAQ
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
News Preview
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2026
DCOY
LISTED
NASDAQ
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
News Preview
Decoy Therapeutics will use the platform, with funding support from the Gates Foundation, to provide widespread access to peptide-conjugate antivirals from Decoy's IMP3ACT™ platform for low- and middle-income countries.CAMBRIDGE, Mass. and HOUSTON, Jan. 13, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a pre...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
NOTV
LISTED
NASDAQ
Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery
News Preview
WEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced a strategic initiative to leverage Life...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
CNVI
LISTED
TSX
Conavi Medical Corp. Announces Closing of $12M Public Offering
News Preview
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
OMCL
LISTED
NASDAQ
Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
News Preview
Omnicell, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the fourth quarter and full year 2025, before market open on Thursday, February 5, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2026
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
News Preview
- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -- Presenting at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 am PT (11:15 am ET) -BOULDER, Colo., Jan. 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle d...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2026
JNJ
LISTED
NYSE
Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
News Preview
New CAPLYTA® (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented SPRAVATO® (esketamine) effects on anhedonia in treatment-resistant depression (TRD) – Phase 3 data post-hoc analyses to be presentedComparative tolerability of adjunctive seltorexant vs. adjunctive...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
FEMY
LISTED
NASDAQ
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
News Preview
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2026
VCEL
LISTED
NASDAQ
Vericel Announces Preliminary 2025 Financial Results and Business Updates
News Preview
Total Revenue Expected to be $276 Million ...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
ANRO
LISTED
NYSE
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
News Preview
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations highlighting new data and analyses supporting the Company’s development programs at the 64th annual meeting of the American College...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
NTRA
LISTED
NASDAQ
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an advancement in molecular residual disease (MRD)-based risk stratification that is expected to extend the company’s leadership in oncology. The new multi-modal model will integrate longitudinal ctDNA and clinical data with digita...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
6446
LISTED
TAI
FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
News Preview
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s sup...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
ZLAB
LISTED
NASDAQ
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today provided an update on the Company’s 2026 strategic priorities and clinical development progress. These updates will be discussed as part of the Company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET....
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2026
GDRX
LISTED
NASDAQ
Surescripts and GoodRx Partner to Advance Patient Price Transparency
News Preview
Surescripts®, the nation’s leading health intelligence network, introduces its Patient Experience product, Script Corner™, to transform the medication experience and empower patients by bringing together prescription benefit data, medication management and personalized engagement. Script Corner will include patient price transparency, including di...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2026
ORMP
LISTED
TLV
Oramed and Lifeward Announce Strategic Transaction
News Preview
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant ShareholderOramed will transfer POD™ platform to Lifeward while retaining management of clinical programOramed will receive 49.9% beneficial ownership interest in Lifeward, a revenue-generating medical robotics company...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
